Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuichi Ando

Showing results (211-220 of 241) with videos related to

Pageof 25
Sort By:
Cancer Chemotherapy and Pharmacology|May 26, 2009
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancerKen-ichi Fujita, Yuichi Ando, Wataru Yamamoto, et al.
Endocrine-Related Cancer|September 16, 2015
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancerFrancis Worden, Martin Fassnacht, Yuankai Shi, et al.
Cancer Medicine|June 23, 2023
Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancerTakahiro Hatta, Tetsunari Hase, Toru Hara, et al.
Journal of Diabetes Investigation|September 3, 2013
Effect of glycemic control on periodontitis in type 2 diabetic patients with periodontal diseaseSayaka Katagiri, Hiroshi Nitta, Toshiyuki Nagasawa, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2018
Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancerSuguru Yamada, Tsutomu Fujii, Yukihiro Yokoyama, et al.
BMC Cancer|April 6, 2017
The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)Goro Nakayama, Kiyoshi Ishigure, Hiroyuki Yokoyama, et al.
Liver Cancer|July 18, 2025
Fever following Treatment with Atezolizumab plus Bevacizumab Predicts Liver Injury in Patients with Unresectable Hepatocellular Carcinoma: A Prospective Observational AnalysisTakanori Ito, Takafumi Yamamoto, Kazuki Nishida, et al.
Nagoya Journal of Medical Science|October 2, 2024
Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective studyTakayuki Okuji, Shintaro Iwama, Tomoko Kobayashi, et al.
Investigational New Drugs|May 12, 2023
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitisTakafumi Yamamoto, Kazuyuki Mizuno, Takanori Ito, et al.
The Oncologist|June 14, 2025
Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse eventsKazuyuki Mizuno, Takanori Ito, Tsunaki Sawada, et al.
Pageof 25

Showing results (211-220 of 241) with videos related to

Sort By:
Pageof 25
Cancer Chemotherapy and Pharmacology|May 26, 2009
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancerKen-ichi Fujita, Yuichi Ando, Wataru Yamamoto, et al.
Endocrine-Related Cancer|September 16, 2015
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancerFrancis Worden, Martin Fassnacht, Yuankai Shi, et al.
Cancer Medicine|June 23, 2023
Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancerTakahiro Hatta, Tetsunari Hase, Toru Hara, et al.
Journal of Diabetes Investigation|September 3, 2013
Effect of glycemic control on periodontitis in type 2 diabetic patients with periodontal diseaseSayaka Katagiri, Hiroshi Nitta, Toshiyuki Nagasawa, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2018
Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancerSuguru Yamada, Tsutomu Fujii, Yukihiro Yokoyama, et al.
BMC Cancer|April 6, 2017
The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)Goro Nakayama, Kiyoshi Ishigure, Hiroyuki Yokoyama, et al.
Liver Cancer|July 18, 2025
Fever following Treatment with Atezolizumab plus Bevacizumab Predicts Liver Injury in Patients with Unresectable Hepatocellular Carcinoma: A Prospective Observational AnalysisTakanori Ito, Takafumi Yamamoto, Kazuki Nishida, et al.
Nagoya Journal of Medical Science|October 2, 2024
Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective studyTakayuki Okuji, Shintaro Iwama, Tomoko Kobayashi, et al.
Investigational New Drugs|May 12, 2023
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitisTakafumi Yamamoto, Kazuyuki Mizuno, Takanori Ito, et al.
The Oncologist|June 14, 2025
Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse eventsKazuyuki Mizuno, Takanori Ito, Tsunaki Sawada, et al.
Pageof 25